Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200

Phase 1Active Not RecruitingNCT06003530

Cytora Ltd.21 enrolled

Overview

Purpose of this phase 1/2a study is to assess the safety and efficacy of administration of allogeneic human oral mucosal stem cells (hOMSCs) in patients suffering from chronic diabetic foot ulcers (DFU).

A prospective, placebo controlled, partially blinded and randomized study, comprising two hOMSC200 dose groups (low \& high) and one placebo treated group of DFU patients (3 groups; n=8 / treatment groups and n=6/ control group). Study employs a 2+2 design for dose escalation. The first two patients recruited were treated with a low dose, in a staggered manner, followed by two patients who were recruited to receive the high dose. The remaining patients (18) are randomized to receive the low dose, high dose, or placebo treatment. The assessors and patients will be blinded to the study treatments. Following administration of hOMSC200 or placebo patients will attend on-site follow up visits for 6 months. During this period safety profile of the investigational product will be assessed as well as measurement of ulcer size. All patients, irrespective of allocated treatment, will receive routine standard of care. Patients will be followed for long term safety with a phone call interview 1 year following the 6 months termination visit. Optional on-site follow up visits will be offered to all patients during this time period.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Diabetic Foot Diabetic Foot Ulcer Diabetic Foot Ulcer Neuropathic

Interventions

hOMSC200BIOLOGICAL

Human Oral Mucosal Stem Cells

PlaceboOTHER

Animal component-free, defined cryopreservation medium with 5% DMSO

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with Type I or Type 2diabetes and with a neuropathic diabetic foot ulcer for longer than 8 weeks. * Size of foot ulcer 0.5-13 cm2 * Ulcer graded I by Wager scale * Ulcer is free of necrotic debris, exhibits no signs of clinical infection * Ulcer area blood circulation meets one of the following criteria: A. Palpable tibialis anterior and posterior arteries in the affected foot; B. ABI range \>0.7 to \<1.3; C. TcPO2\>30mmHg Exclusion Criteria: * Ulcer is of non-diabetic pathophysiology * The ulcer has decreased in size by \>=30% after the screening visit (week -2 to -4 before treatment) * Severe hepatic deficiency * Glycated hemoglobin A1C (HbA1C) level of \>12% * Postprandial blood sugar \> 350mg/dl * Require antibiotics to treat the target wound infection within 14 days prior to treatment * Evidence of current wound infection including pus drainage from wound site * Severe renal failure (GFR\<30) including subject on renal dialysis * Pregnant or breastfeeding * Was receiving oral or parenteral corticosteroids, immunosuppressives, or cytotoxic agents prior to 4 weeks from screening * Patient receiving anticoagulation therapy except for aspirin * Underwent wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days prior to screening visit

Locations (1)

Shaare Zedek Medical Center

Jerusalem, Israel

Outcomes

Primary Outcomes

Treatment related adverse events

Occurrence of treatment-related adverse events assessed by common terminology criteria for adverse events (CTCAE) following recruitment, hOMSC200 administration (ID), and during the follow up.

Time frame: 6 months

Secondary Outcomes

Wound healing

Percentage of wound surface area reduction

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.